Descriptive data | All patients (N=108) | Patient with relevant TR (N=44) | Patients without relevant TR (N=64) | P value |
Male (%) | 65 (60%) | 21 (48%) | 44 (69%) | |
Age (years) | 70±12.12 | 75±8.56 | 67±12.94 | <0.001 |
BMI (kg/m²) | 27.1±4.41 | 26.7±3.53 | 27.2±10.6 | 0.559 |
Weight (kg) | 78.9±15.81 | 77.5±18.49 | 79.8±14.49 | 0.50 |
LVEF biplane (%) | 48.7±15.4 | 47.1±14.6 | 49.7±15.9 | 0.42 |
Lead (%) | 19 (17.6%) | 11 (25%) | 8 (12,5%) | |
LVDd/ LVDs | 50.9/41.4 | 51.1/40.3 | 50.8/42.1 | 0.876 |
LVEDV biplane (mL) | 113.7±35.35 | 103.4±35.5 | 120.18±6.36 | 0.164 |
LVESV biplane (mL) | 62.7±39.59 | 59.5±21.21 | 64.4±28.84 | 0.597 |
SV (mL) | 49.1±19.09 | 43.36±16.97 | 52.5±24.48 | 0.048 |
TR: PISA (mm) 2D | 3.9±3.5 | 6.8±0.5 | 1.8±2.5 | <0.001 |
TR: VC (mm) | 4.5±4.5 | 8.4±4.21 | 1.8±1.91 | <0.001 |
TR: RV diameter (enddiastolic) (mm) | 43.4±9.4 | 48.4±10.15 | 40.1±7.21 | <0.001 |
TR:ERO(cm²) 2D TTE | 0.46±0.56 | 0.9±0.61 | 0.1±0.12 | <0.001 |
TASV cm/s | 10.3±3.30 | 8.86±2.63 | 11.3±3.41 | 0.005 |
TAPSE (mm) | 17.3±5.05 | 15.45±4.11 | 18.5±5.25 | 0.001 |
Indication for TOE cardioversion | 32 (29.6%) | 4 (9,1%) | 28 (43.7%) | |
Valve evaluation (MV, TV, AV) | 65 (60.2 %) | 40 (91%) | 25 (39%) | |
PFO/ASD | 11 (10.1%) | 11 (17.2%) |
ASD, defect of atrial septum ; BMI, body mass index; ERO, effective regurgitant orifice; LVDd/LVDs, left ventricular diameter diastolic/left ventricular diameter systolic; LVeDV, left ventriclar end diastolic volume; LVEF, left ventricular ejection fraction; LVeSV, left ventricular endsystolic volume; MV, mitral valve; PFO, persistent foramen ovale; PISA, proximal isovolumetric velocity area; RV, right ventricular; SV, Stroke volume; TAPSE, tricuspid annular plane systolic excursion; TASV, tricuspid annular systolic velocity; TOE, transoesophageal echocardiography; TR, tricuspid regurgitation; TTE, transthoracic echocardiography; TV, tricuspid valve; VC, vena contracta.